Calreticulin (CALR) Mutation Analysis
Also known as: Myeloproliferative neoplasm, PMF, Essential Thrombocythemia (ET), Polycythemia Vera (PV), ET
Use
This advanced DNA‑based next‑generation sequencing (NGS) assay analyzes leukocytes from whole blood or bone marrow aspirate for frameshift mutations in exon 9 of the CALR gene, which are associated with myeloproliferative neoplasms (MPN), particularly essential thrombocythemia (ET) and primary myelofibrosis (PMF). CALR mutations are mutually exclusive with JAK2 and MPL mutations and confer different prognostic implications compared to JAK2‑mutated cases.
Special Instructions
Not provided.
Limitations
Not provided.
Methodology
NGS
Biomarkers
Result Turnaround Time
5-7 days
Related Documents
For more information, please review the documents below
Specimen
Whole Blood
Volume
4 mL whole blood
Minimum Volume
3 mL whole blood
Container
EDTA (lavender‑top) tube
Causes for Rejection
Frozen specimens unacceptable
Stability Requirements
| Temperature | Period |
|---|---|
| Room Temperature | 7 days |
| Refrigerated | 7 days |
| Frozen | 1 year (extracted DNA); unacceptable for specimens |
